Calvert Research and Oncoceutics Announce Investment Partnership to Advance ONC201 to an IND Filing

Calvert Research and Oncoceutics Announce Investment Partnership to Advance ONC201 to an IND Filing

CARY, NC and HUMMELSTOWN, PA (October 1, 2013). Calvert Research, LLC and Oncoceutics, Inc. announced the execution of an Investment Partnership Agreement to support completion of preclinical studies for ONC201, Oncoceutics' experimental anti-cancer compound.

Under the terms of the Agreement, Calvert Research will utilize the extensive resources of its CRO affiliate, Calvert Laboratories, Inc., to complete animal pharmacology, toxicology, and pharmacokinetic testing and conduct bioanalytical studies on ONC201 to support the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by the end of 2013. In conjunction with performing these studies, Calvert Research has made a significant investment in Oncoceutics in the form of a Convertible Promissory Note that can be converted into equity in Oncoceutics under certain terms and conditions.

ONC201 is a small molecule that has shown potent anti-tumor effects in multiple mouse models of human cancer, including brain, colon, breast, lung, and other tumors. ONC201 elevates the expression of TRAIL (TNF-related apoptosis-inducing ligand) and its death receptor DR5 on the surface of tumor cells to trigger a tumor-specific cytotoxic response. ONC201′s exclusive ability to stimulate expression of both the death receptor and TRAIL leads to an increased spectrum of anti-tumor activity, which may offer a meaningful therapeutic benefit to cancer patients in numerous clinical settings.

"We are pleased to add Oncoceutics to our investment portfolio" said Dr. Michael Recny, President of Calvert Research. "This deal represents another outstanding example of how we implement our investment thesis by sharing both capital and development risk with early stage companies that have novel, highly promising experimental drugs. Our partners benefit from our extensive drug development expertise and ability to leverage the world-class capabilities of our affiliate, Calvert Laboratories into a meaningful capital investment in their company."

"We are delighted that Calvert invested in Oncoceutics to help us advance ONC201 toward human testing" remarked Dr. Wolfgang Oster, CEO of Oncoceutics. "This investment partnership is indicative of Calvert's entrepreneurial spirit as well as our aligned interests, and it validates the compelling data with ONC201 that have already been generated."


About Oncoceutics, Inc.

Oncoceutics, Inc. is a drug discovery and development company, run by a leadership team with an outstanding track record of success in drug development that seeks to develop and commercialize novel anti-cancer therapeutics. The company investigates small molecule compounds to overcome dysfunctional p53 and related pathways, the most frequently mutated in human cancers. The most advanced of these molecules, ONC201, is the subject of a $1.3M grant from the Pennsylvania Department of Health that will be used to complete the preclinical and administrative components of an IND application, obtain IND and IRB clinical protocol approval, and conduct the first Phase I/II trial in humans. Oncoceutics is on track to file an IND application by the end of 2013.

Oncoceutics Contact:
Lee Schalop, M.D.
Chief Business Officer
[email protected]

About Calvert Laboratories, Inc.

Calvert Labs provides a wide array of preclinical services to help clients navigate their GLP testing needs prior to advancing their discoveries into clinical trials.  In addition to lead identification and lead optimization services, Calvert's core service offerings include toxicology, pharmacology, safety pharmacology, ADME, immunotoxicology and immunology.

About Calvert Holdings, Inc.

Formed in 1996, Calvert Holdings, Inc. is a privately-held company that provides vision, resources and business leadership for all of the companies we develop or acquire. Calvert Holdings is currently the parent company of Calvert Labs and Calvert Research.

Calvert Contact:
Dr. Michael A. Recny
EVP and Chief Investment Officer, Calvert Holdings, Inc.
President, Calvert Research, LLC
(919) 459-8669
[email protected]

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.